$BIAF

bioAffinity Technologies (BIAF) rose 47.95% after announcing its AI-based lung-cancer surveillance tool, CyPath Lung, and a 1-for-15 reverse stock split. Q2 test volume surged 216% YoY, but the company reported a $3.4M net loss and $2.4M cash. Clinical study results showed 92% sensitivity and 88% accuracy. The company faces challenges in scaling revenue and managing dilution risks.

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

BioAffinity Technologies (BIAF) shares rose 40% after announcing plans to expand use of its CyPath Lung test for lung cancer surveillance. The stock traded at $6.40, up from $4.56, with high volume.

BioAffinity Technologies (BIAF) signed a nationwide distribution agreement with AvMEDICAL to expand access to its CyPath Lung diagnostic test in federal healthcare agencies. The partnership leverages AvMEDICAL's government procurement expertise. BIAF stock closed at $0.47, down 11.24% in pre-market trading.

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules SAN ANTONIO, TX – August 13, 2026 – bioAffinity Technologies, Inc . (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung CyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and advances longitudinal clinical

bioAffinity Technologies (Nasdaq: BIAF) said it will partner with Pictor, Inc. to develop and commercialize next-generation asthma and COPD diagnostics. The collaboration combines bioAffinity flow cytometry with Pictor targeted proteomic cytokine profiling, with tests expected to launch as CLIA Laboratory Developed Tests. bioAffinity will own IP for the tests; Pictor retains its platform IP.

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is entered into and made effective as of June 16, 2026, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “ Company ”), and eac

bioAffinity Technologies' stockholders approved several significant proposals at their 2026 Annual Meeting. Key approvals include expanding the 2024 Equity Incentive Compensation Plan to 1,000,000 shares, authorizing potential non-public offerings, and allowing a discretionary reverse stock split ranging from 1-for-2 to 1-for-250. These actions provide the company with substantial flexibility for future compensation, fundraising, and capital structure adjustments, although they also introduce potential share dilution.

bioAffinity Technologies (BIAF) released a case study demonstrating how its CyPath® Lung diagnostic test helped a physician defer an unnecessary biopsy for a patient with a suspicious pulmonary nodule. Despite imaging and risk models suggesting a high likelihood of cancer, the noninvasive sputum-based test indicated "Unlikely Malignancy," leading to a follow-up scan that showed the nodule had resolved. This highlights CyPath® Lung's potential to provide objective data for managing indeterminate lung nodules, especially in high-risk patients where invasive procedures carry significant risks.